Midazolam + Belumosudil Interaction
Unknowninteraction on record
Description
Concomitant use of REZUROCK with sensitive CYP3A substrates (e.g., midazolam) is predicted to increase CYP3A substrate exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of adverse reactions related to these substrates.
Source: FDA drug label - belumosudil